Background: Despite the availability of patented non-invasive methods, evaluation of the degrees of liver fibrosis remains difficult when conducting a retrospective study. Such inadequacy is largely caused by requirement of biochemical parameters rarely performed in routine clinical tests. We developed a novel fibrosis HB-F score using commonly performed tests for HBV infected patients. Methods. 424 patients with chronic HBV infection were included. Using clinical and virological data, HB-F score was developed from a training cohort (n = 213) and validated in a separate cohort (n = 211). The performance was compared with five other unpatented scores using ROC curves. Results: Univariate and multivariate analysis revealed that age, AST/ALT ratio, platelet count and prothrombin time prolongation were significantly associated with the ISHAK fibrosis score, and were used to calculate the HB-F score. When HB-F was used to assess prominent fibrosis and cirrhosis, the AUC was 0.81 and 0.80 respectively in the training cohort, and 0.80 and 0.76 respectively in the validation cohort. HB-F had the highest AUC compared with other scores. Furthermore, in assessing paired liver biopsies with increase or decrease of ISHAK scores, HB-F showed significant change in the same direction. Conclusions: A new non-invasive score was developed, which could be used to assess severity of liver fibrosis in retrospective longitudinal studies in HBV patients. © 2013 Hsu et al.; licensee BioMed Central Ltd.
CITATION STYLE
Hsu, C. W., Liang, K. H., Huang, S. F., Tsao, K. C., & Yeh, C. T. (2013). Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Research Notes, 6(1). https://doi.org/10.1186/1756-0500-6-212
Mendeley helps you to discover research relevant for your work.